Reuters logo
BRIEF-Capricor Therapeutics retains full rights to CAP-1002 as Janssen Biotech decides not to exercise option
July 6, 2017 / 10:47 PM / 4 months ago

BRIEF-Capricor Therapeutics retains full rights to CAP-1002 as Janssen Biotech decides not to exercise option

July 6 (Reuters) - Capricor Therapeutics Inc:

* Capricor therapeutics- no payments between capricor and janssen are required to be made in relation to this decision

* Capricor therapeutics retains full rights to cap-1002 as janssen biotech, inc. Decides not to exercise option

* Capricor therapeutics inc-in connection with decision, collaboration agreement, license option entered into between co and janssen terminated

* Capricor therapeutics inc-no payments between capricor and janssen are required to be made in relation to decision

* Capricor therapeutics-co to have fully paid-up non-exclusive license under patents controlled by janssen utilized in production of clinical trial materials

* Capricor therapeutics-to have non-exclusive license to publish, disclose, use information of janssen utilized in production of clinical trial materials Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below